Stockscreener 앱 받기
75.95
3.40%
-2.67
시간 외 거래:
75.95
전일 마감가:
$78.62
열려 있는:
$78.62
하루 거래량:
1.04M
Relative Volume:
0.94
시가총액:
$4.72B
수익:
$209.18M
순이익/손실:
$52.04M
주가수익비율:
106.60
EPS:
0.7125
순현금흐름:
$37.10M
1주 성능:
+0.93%
1개월 성능:
+17.15%
6개월 성능:
+66.89%
1년 성능:
+62.43%
1일 변동 폭
$75.53
$80.43
1주일 범위
$74.80
$80.43
52주 변동 폭
$33.31
$93.25
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
75.95 | 4.89B | 209.18M | 52.04M | 37.10M | 0.7125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-12 | 개시 | Leerink Partners | Outperform |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - ACCESS Newswire
Protagonist (PTGX) to present 4 rusfertide presentations at ASH, including Phase 3 VERIFY - Stock Titan
Is Protagonist Therapeutics Inc. stock entering bullish territoryMarket Weekly Review & Step-by-Step Trade Execution Guides - newser.com
Protagonist Therapeutics Inc. stock chart pattern explainedMarket Risk Summary & Fast Moving Market Watchlists - newser.com
How rising interest rates impact Protagonist Therapeutics Inc. stock2025 Key Lessons & Reliable Breakout Forecasts - newser.com
How Protagonist Therapeutics Inc. stock responds to policy changesJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
Leerink Partnrs Issues Optimistic Forecast for PTGX Earnings - MarketBeat
Can Protagonist Therapeutics Inc. hit a new high this month2025 Earnings Impact & Short-Term High Return Ideas - newser.com
How strong is Protagonist Therapeutics Inc. stock revenue growth2025 Momentum Check & Safe Capital Preservation Plans - newser.com
Price action breakdown for Protagonist Therapeutics Inc.July 2025 Recap & Free Fast Gain Swing Trade Alerts - newser.com
Is Protagonist Therapeutics Inc. stock a top pick in earnings season2025 Momentum Check & Weekly Return Optimization Alerts - newser.com
Protagonist Therapeutics, Inc. $PTGX is Moody Aldrich Partners LLC's 2nd Largest Position - MarketBeat
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Donaldsonville Chief
What is Wedbush's Estimate for PTGX FY2029 Earnings? - MarketBeat
Protagonist Therapeutics (PTGX) to Release Earnings on Thursday - MarketBeat
Will Protagonist Therapeutics Inc. stock benefit from commodity pricesProduct Launch & Daily Entry Point Alerts - newser.com
How Protagonist Therapeutics Inc. stock reacts to job market data2025 Market Outlook & Expert Curated Trade Setups - newser.com
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - Asbury Park Press
Protagonist Therapeutics (PTGX): Assessing Valuation After Breakthrough Phase 2b Results and Johnson & Johnson’s Phase 3 Launch - Sahm
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
How to track smart money flows in Protagonist Therapeutics Inc.2025 Retail Activity & Risk Controlled Daily Trade Plans - newser.com
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $86.00 at Wedbush - MarketBeat
Protagonist Therapeutics (PTGX) Price Target Increased by 10.06% to 78.69 - Nasdaq
BTIG Research Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
State of New Jersey Common Pension Fund D Sells 12,711 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wedbush Maintains Protagonist Therapeutics (PTGX) Outperform Recommendation - Nasdaq
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):